A leading global aesthetic device company has announced that its proprietary Sublative™ technology has received CE Mark indication for the effective treatment of stretch marks and acne scars.
The new treatment protocols are now available on all of the Syneron Sublative compatible systems, which include elōs Plus™, eTwo™ and eMatrix™.
With its new CE Mark clearance, Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime.
The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption.
Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments. After treatment with Sublative, the appearance of stretch marks and acne scars are greatly reduced.
“We have extensively studied the Sublative approach in the treatment of striae and found a noticeable and measurable improvement in the depth, width and color of striae after very few treatments,” states Maurice Adatto, M.D., Dermatologic Surgeon, Geneva, Switzerland, founder & Medical Director of SKINPULSE Derm & Laser Centres, Lecturer at Bern University Hospital.
The typical Sublative protocol consists of three to five treatments, spaced four to six weeks apart. Post treatment, patients can expect tone and texture improvements as a result of increased levels of collagen and elastin and new healthy skin cells, which are produced.
“Sublative resurfacing is my first line therapy for acne scarring, particularly for skin types IV – VI.” said Amy Taub, MD from Chicago, Illinois, founder and Medical Director of Advanced Dermatology and skinfo, Clinical Assistant Professor at Northwestern University, Feinberg School of Medicine.
“I find it to be superior to non-ablative laser resurfacing with respect to downtime, discomfort and degree of complications such as acne and post inflammatory hyperpigmentation,” she adds.
The addition of stretch mark treatment further expands Syneron’s clinical utility and will allow physician customers to address a large segment of the aesthetic market.
“We have received very positive physician and patient feedback on the Sublative technology since its introduction in 2009,” states Amit Meridor, Syneron’s CEO.
“This patented fractional bi-polar radio frequency technology delivers excellent outcomes with little-to-no downtime and is a safe and more effective treatment alternative for all skin tones. We continue to create innovation solutions that further drive the aesthetic industry forward.”
Syneron unveiled the treatment protocols for its Sublative compatible platforms at the 12th Annual Anti-Aging Medicine World Congress in Monte Carlo, Monaco, in April 2014.
For more information visit www.syneron-candela.co.uk
//BOX OUT//
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
